Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
08.02.2025 01:51:26
|
AbbVie: FDA Approves Emblaveo - Metronidazole Combination For Complicated Intra-Abdominal Infections
(RTTNews) - AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first fixed-dose, intravenous monobactam/ Beta -lactamase inhibitor combination antibiotic. In combination with metronidazole, Emblaveo is approved for patients aged 18 and older who have limited or no alternative options for treating complicated intra-abdominal infections (cIAI). It is effective against several susceptible Gram-negative microorganisms, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
According to the company, Emblaveo will be available for commercial use in the U.S. in third quarter 2025.
Emblaveo was jointly developed with Pfizer. AbbVie holds the rights to commercialize the therapy in the U.S. and Canada, with Pfizer responsible for commercialization in all other areas.
In 2019, the FDA granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for EMBLAVEO. The QIDP Designation provides certain incentives for the development of new antibiotics, including priority review and eligibility for the FDA's Fast Track Designation, and a five-year regulatory exclusivity extension. The Fast Track Designation is designed to facilitate the development of and accelerate the review of drugs to treat serious conditions that do not have sufficient treatment options.
ABBV closed Friday's regular trading at $190.60 down $2.37 or 1.23%. But in the after-hours trading, the stock gained $0.16 or 0.08%.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
20.10.25 |
ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar (dpa-AFX) | |
14.10.25 |
Novo Nordisk-Aktie im Minus: Gelingt auch hier ein US-Deal wie bei Pfizer und AstraZeneca? (finanzen.at) | |
14.10.25 |
S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor 5 Jahren eingebracht (finanzen.at) | |
13.10.25 |
AstraZeneca-Aktie im Minus: Zollnachlässe für Preissenkungen - AstraZeneca folgt Pfizer-Beispiel in den USA (dpa-AFX) | |
07.10.25 |
S&P 500-Papier Pfizer-Aktie: So viel hätte eine Investition in Pfizer von vor 3 Jahren gekostet (finanzen.at) | |
01.10.25 |
Pfizer-Deal beflügelt Pharmaaktien: Merck, Bayer, Novo Nordisk, J&J & Co. im Plus (dpa-AFX) | |
01.10.25 |
AKTIEN IM FOKUS 2: US-Deal mit Pfizer hilft gesamter Pharmabranche (dpa-AFX) | |
30.09.25 |
Pluszeichen in New York: S&P 500 schlussendlich fester (finanzen.at) |
Analysen zu Pfizer Inc.mehr Analysen
20.10.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
02.10.25 | Pfizer Buy | Jefferies & Company Inc. | |
01.10.25 | Pfizer Buy | Jefferies & Company Inc. | |
30.09.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
24.09.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
AbbVie Inc | 198,80 | 1,02% |
|
Pfizer Inc. | 21,44 | 1,13% |
|